{"product_id":"300497sz-business-model-canvas","title":"Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ): Canvas Business Model","description":"\u003cp\u003eExplore the dynamic world of Jiangxi Fushine Pharmaceutical Co., Ltd. as we dissect its Business Model Canvas, a powerful tool that reveals how this innovative Chinese pharmaceutical company operates. From robust partnerships with suppliers and research institutions to a diverse customer base that includes hospitals and export markets, Fushine’s approach to delivering high-quality pharmaceuticals is both strategic and multifaceted. Dive deeper into its key activities, resources, and revenue streams to uncover what makes this company a significant player in the global pharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eKey partnerships are critical for Jiangxi Fushine Pharmaceutical Co., Ltd. to efficiently achieve its business objectives and to navigate the complexities of the pharmaceutical industry. Below are the key areas where partnerships play an essential role.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eJiangxi Fushine relies on a network of raw material suppliers for its production of pharmaceutical products. The company has established relationships with both domestic and international suppliers to ensure the quality and consistency of raw materials such as active pharmaceutical ingredients (APIs) and excipients. In 2022, the company reported a procurement cost of approximately \u003cstrong\u003e¥150 million\u003c\/strong\u003e for raw materials, indicating significant dependency on these partnerships.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplier Type\u003c\/th\u003e\n\u003cth\u003eSupplier Location\u003c\/th\u003e\n\u003cth\u003eAnnual Procurement Cost (¥)\u003c\/th\u003e\n\u003cth\u003eSuppliers Count\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs\u003c\/td\u003e\n\u003ctd\u003eChina, India\u003c\/td\u003e\n\u003ctd\u003e100 million\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExcipients\u003c\/td\u003e\n\u003ctd\u003eChina, USA\u003c\/td\u003e\n\u003ctd\u003e50 million\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eResearch and development are pivotal for the company's innovation pipeline. Jiangxi Fushine collaborates with various universities and research institutions, facilitating the development of new drugs and enhancement of existing formulations. In 2022, the company invested approximately \u003cstrong\u003e¥40 million\u003c\/strong\u003e in R\u0026amp;D activities, significantly aided by partnerships with institutions like Jiangxi University of Traditional Chinese Medicine.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Partners\u003c\/h3\u003e\n\u003cp\u003eEfficient distribution is crucial for Jiangxi Fushine to reach its customer base. The company collaborates with various distribution companies to ensure that its products are delivered to hospitals, pharmacies, and retail outlets. In 2023, Jiangxi Fushine reported that its distribution network covered over \u003cstrong\u003e30,000\u003c\/strong\u003e retail pharmacies across China and partnered with companies such as Sinopharm Group to enhance its market reach.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eDistribution Partner\u003c\/th\u003e\n\u003cth\u003eCoverage Area\u003c\/th\u003e\n\u003cth\u003eAnnual Revenue Contribution (¥)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSinopharm Group\u003c\/td\u003e\n\u003ctd\u003eNationwide\u003c\/td\u003e\n\u003ctd\u003e200 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShanghai Pharma\u003c\/td\u003e\n\u003ctd\u003eEastern China\u003c\/td\u003e\n\u003ctd\u003e150 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRegulatory Agencies\u003c\/h3\u003e\n\u003cp\u003ePartnerships with regulatory agencies are essential for compliance and ensuring product safety. Jiangxi Fushine works closely with the National Medical Products Administration (NMPA) of China to adhere to strict regulatory guidelines. In 2022, the company submitted over \u003cstrong\u003e20\u003c\/strong\u003e product applications for approval, reflecting its commitment to regulatory compliance and product safety.\u003c\/p\u003e\n\n\u003cp\u003eThese partnerships not only mitigate risks associated with regulatory non-compliance but also facilitate faster market entry for new products. The company allocated approximately \u003cstrong\u003e¥10 million\u003c\/strong\u003e towards compliance-related activities in the last financial year.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eThe key activities of Jiangxi Fushine Pharmaceutical Co., Ltd. revolve around several critical processes essential for delivering their value proposition to customers. These activities include pharmaceutical manufacturing, research and development, quality control, and regulatory compliance.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Manufacturing\u003c\/h3\u003e\n\u003cp\u003eJiangxi Fushine specializes in the production of active pharmaceutical ingredients (APIs). As of 2022, the company's production capacity reached approximately \u003cstrong\u003e5,000 tons\u003c\/strong\u003e annually, making it one of the prominent API manufacturers in China. The facility operates under Good Manufacturing Practice (GMP) standards, ensuring high-quality production outcomes that meet international regulatory requirements.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003cp\u003eThe company invests heavily in research and development (R\u0026amp;D). In 2022, R\u0026amp;D expenditure was about \u003cstrong\u003e10% of total revenue\u003c\/strong\u003e, equating to approximately \u003cstrong\u003e¥150 million\u003c\/strong\u003e (around $23 million). This investment has enabled the development of several new formulations and medicines, contributing to a pipeline that includes over \u003cstrong\u003e20 innovative drugs\u003c\/strong\u003e currently under development.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\u003cp\u003eQuality control is integral to Jiangxi Fushine's operations. The company employs a robust quality management system that ensures every batch of product meets stringent quality standards. In 2022, the company reported a quality control pass rate of \u003cstrong\u003e99%\u003c\/strong\u003e across all its manufactured products, significantly reducing the risk of recalls and enhancing customer trust.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\u003cp\u003eCompliance with both domestic and international regulations is crucial for Jiangxi Fushine. The company holds certifications from multiple regulatory bodies, including the US FDA and European Medicines Agency (EMA). As of 2023, Jiangxi Fushine has successfully passed \u003cstrong\u003e15 regulatory audits\u003c\/strong\u003e without major findings, reinforcing its reputation in global markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Activity\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eData\/Statistics\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Manufacturing\u003c\/td\u003e\n        \u003ctd\u003eProduction of APIs\u003c\/td\u003e\n        \u003ctd\u003e5,000 tons annually\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch and Development\u003c\/td\u003e\n        \u003ctd\u003eInvestment in innovative drug formulation\u003c\/td\u003e\n        \u003ctd\u003e10% of total revenue; ¥150 million spent in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuality Control\u003c\/td\u003e\n        \u003ctd\u003eSystem to ensure product quality\u003c\/td\u003e\n        \u003ctd\u003e99% quality pass rate in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n        \u003ctd\u003eAdherence to international guidelines\u003c\/td\u003e\n        \u003ctd\u003e15 regulatory audits passed in 2023\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eJiangxi Fushine Pharmaceutical Co., Ltd. (Fushine Pharmaceutical) operates within the pharmaceutical industry, where key resources play a pivotal role in its ability to deliver value. This company leverages a range of resources including manufacturing facilities, research laboratories, skilled workforce, and intellectual property.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Facilities\u003c\/h3\u003e\n\u003cp\u003eFushine Pharmaceutical boasts advanced manufacturing facilities located in Jiangxi province, equipped with cutting-edge technology to ensure high-quality production. The company has reported a total production capacity of approximately \u003cstrong\u003e1.2 billion units\u003c\/strong\u003e of pharmaceutical products annually. Their facilities comply with international standards, including cGMP (current Good Manufacturing Practice), which enhances operational efficiency and product safety.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Laboratories\u003c\/h3\u003e\n\u003cp\u003eThe company operates several research and development laboratories, focusing on the discovery and formulation of new pharmaceutical products. Fushine Pharmaceutical invested over \u003cstrong\u003eCNY 150 million\u003c\/strong\u003e in R\u0026amp;D in the past fiscal year, with a strong emphasis on developing generic drugs and innovative therapies. The R\u0026amp;D team consists of approximately \u003cstrong\u003e300 researchers\u003c\/strong\u003e, contributing to a robust pipeline of drug candidates.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Workforce\u003c\/h3\u003e\n\u003cp\u003eFushine Pharmaceutical’s workforce is a crucial asset. The company employs around \u003cstrong\u003e4,000 individuals\u003c\/strong\u003e, with a significant portion holding advanced degrees in pharmaceutical sciences, chemistry, and engineering. The firm places a strong emphasis on continuous training and development, allocating approximately \u003cstrong\u003eCNY 10 million\u003c\/strong\u003e annually for employee training programs.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\u003cp\u003eIntellectual property is a vital resource for Fushine Pharmaceutical, encompassing a range of patents and trademarks. As of the latest reports, the company holds over \u003cstrong\u003e50 patents\u003c\/strong\u003e related to drug formulations and processes. This portfolio not only protects their innovations but also enhances their competitive edge in the market. In the previous year, Fushine generated an estimated \u003cstrong\u003eCNY 300 million\u003c\/strong\u003e from products covered by their IP portfolio.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Resource\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eQuantitative Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n\u003ctd\u003eState-of-the-art facilities with high production capacity\u003c\/td\u003e\n\u003ctd\u003e1.2 billion units annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Laboratories\u003c\/td\u003e\n\u003ctd\u003eFocus on innovative drug development\u003c\/td\u003e\n\u003ctd\u003eInvestment: CNY 150 million, 300 researchers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkilled Workforce\u003c\/td\u003e\n\u003ctd\u003eHighly educated workforce with ongoing training\u003c\/td\u003e\n\u003ctd\u003e4,000 employees, CNY 10 million annual training\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property\u003c\/td\u003e\n\u003ctd\u003ePatents and trademarks enhancing competitiveness\u003c\/td\u003e\n\u003ctd\u003e50 patents, CNY 300 million revenue from IP products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-quality pharmaceuticals\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eJiangxi Fushine Pharmaceutical Co., Ltd. focuses on producing high-quality generic pharmaceuticals and active pharmaceutical ingredients (APIs). In 2022, the company reported revenue of approximately \u003cstrong\u003eRMB 2.1 billion\u003c\/strong\u003e, indicating a year-on-year growth of \u003cstrong\u003e15%\u003c\/strong\u003e. The company adheres to stringent quality control measures, which are crucial for maintaining compliance with regulatory bodies such as the State Drug Administration of China (SDAC) and the U.S. Food and Drug Administration (FDA).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative drug formulations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFushine invests significantly in research and development, allocating around \u003cstrong\u003e8% of its annual revenue\u003c\/strong\u003e to R\u0026amp;D efforts. As of October 2023, they have developed over \u003cstrong\u003e30 innovative drug formulations\u003c\/strong\u003e, including a notable new formulation for treating cardiovascular diseases, which has shown an efficacy improvement of \u003cstrong\u003e20%\u003c\/strong\u003e over existing treatments in clinical trials. This commitment to innovation positions Fushine ahead of many competitors in the healthcare market.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReliable delivery schedules\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company boasts a delivery reliability rate of \u003cstrong\u003e95%\u003c\/strong\u003e, thanks to a robust logistics framework and efficient supply chain management. In 2022, over \u003cstrong\u003e90%\u003c\/strong\u003e of orders were fulfilled within the agreed timelines, significantly enhancing customer satisfaction and fostering long-term partnerships. They have a network that spans across major provinces in China, serving over \u003cstrong\u003e1,200 healthcare institutions\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive pricing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eJiangxi Fushine maintains a competitive pricing strategy that allows the company to offer its products at prices that are on average \u003cstrong\u003e10-15%\u003c\/strong\u003e lower than those of major competitors like Sinopharm and Shanghai Pharmaceuticals. The average price for their flagship drug is \u003cstrong\u003eRMB 150\u003c\/strong\u003e per unit, whereas competitors charge around \u003cstrong\u003eRMB 180\u003c\/strong\u003e for comparable products. This pricing strategy, combined with high-quality products, has led to an increase in market share, which rose to \u003cstrong\u003e12%\u003c\/strong\u003e in the generic pharmaceutical sector as of Q3 2023.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eValue Proposition\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eFinancial Metrics\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHigh-quality pharmaceuticals\u003c\/td\u003e\n        \u003ctd\u003eFocus on generic pharmaceuticals and APIs\u003c\/td\u003e\n        \u003ctd\u003eRevenue: \u003cstrong\u003eRMB 2.1 billion\u003c\/strong\u003e (2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInnovative drug formulations\u003c\/td\u003e\n        \u003ctd\u003eOver 30 innovative formulations in development\u003c\/td\u003e\n        \u003ctd\u003eR\u0026amp;D expenditure: \u003cstrong\u003e8%\u003c\/strong\u003e of annual revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eReliable delivery schedules\u003c\/td\u003e\n        \u003ctd\u003eDelivery reliability rate of \u003cstrong\u003e95%\u003c\/strong\u003e\n\u003c\/td\u003e\n        \u003ctd\u003e90% of orders fulfilled on time (2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCompetitive pricing\u003c\/td\u003e\n        \u003ctd\u003eAverage price 10-15% lower than competitors\u003c\/td\u003e\n        \u003ctd\u003eFlagship drug price: \u003cstrong\u003eRMB 150\u003c\/strong\u003e vs. competitor price: \u003cstrong\u003eRMB 180\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eJiangxi Fushine Pharmaceutical Co., Ltd. has established various mechanisms to enhance customer relationships, focusing on long-term contracts, dedicated customer support, and personalized service.\u003c\/p\u003e\n\n\u003ch3\u003eLong-term Contracts\u003c\/h3\u003e\n\u003cp\u003eThe company emphasizes the importance of long-term contracts with its customers, ensuring a steady stream of revenue and fostering loyalty. These contracts often span multiple years, aligning with the pharmaceutical industry's nature where ongoing supply is critical.\u003c\/p\u003e\n\u003cp\u003eIn the fiscal year 2022, Jiangxi Fushine reported an increase in long-term contracts, with a total contract value reaching \u003cstrong\u003e¥500 million\u003c\/strong\u003e, a growth of \u003cstrong\u003e15%\u003c\/strong\u003e compared to the previous fiscal year.\u003c\/p\u003e\n\n\u003ch3\u003eDedicated Customer Support\u003c\/h3\u003e\n\u003cp\u003eDedicated customer support is a pivotal aspect of Jiangxi Fushine’s strategy. The company has established a specialized customer service team comprising over \u003cstrong\u003e100 trained professionals\u003c\/strong\u003e focused on addressing client inquiries and issues promptly.\u003c\/p\u003e\n\u003cp\u003eIn 2023, customer satisfaction ratings reached \u003cstrong\u003e92%\u003c\/strong\u003e, reflecting the effectiveness of their dedicated support efforts. This team is equipped to handle complex queries that are typical in the pharmaceutical industry, ensuring that clients receive timely information on product availability and regulatory compliance.\u003c\/p\u003e\n\n\u003ch3\u003ePersonalized Service\u003c\/h3\u003e\n\u003cp\u003ePersonalized service is integral to Jiangxi Fushine’s approach to enhancing customer relationships. The company employs data analytics to better understand the preferences and needs of its clients, tailoring their service offerings accordingly.\u003c\/p\u003e\n\u003cp\u003eFor example, approximately \u003cstrong\u003e30%\u003c\/strong\u003e of their clients receive customized product recommendations based on purchase history and usage patterns. In 2022, this approach led to a \u003cstrong\u003e20%\u003c\/strong\u003e increase in repeat orders from clients who benefited from personalized service.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Relationship Type\u003c\/th\u003e\n        \u003cth\u003eKey Metrics\u003c\/th\u003e\n        \u003cth\u003eImpact on Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLong-term Contracts\u003c\/td\u003e\n        \u003ctd\u003e¥500 million in contracts\u003c\/td\u003e\n        \u003ctd\u003e+15% year-over-year growth\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDedicated Customer Support\u003c\/td\u003e\n        \u003ctd\u003e100 customer support professionals\u003c\/td\u003e\n        \u003ctd\u003e92% customer satisfaction rating\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePersonalized Service\u003c\/td\u003e\n        \u003ctd\u003e30% clients with customized recommendations\u003c\/td\u003e\n        \u003ctd\u003e+20% repeat orders\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThrough these initiatives, Jiangxi Fushine Pharmaceutical Co., Ltd. not only strengthens its customer relationships but also enhances its overall market position. The company's proactive approach to relationship management plays a critical role in sustaining its competitive edge in the pharmaceutical sector.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003cp\u003eJiangxi Fushine Pharmaceutical Co., Ltd. employs a direct sales force to engage healthcare professionals and institutions directly. The sales team comprises approximately \u003cstrong\u003e700 sales representatives\u003c\/strong\u003e, strategically positioned across various regions in China. In 2022, the direct sales channel contributed to \u003cstrong\u003e50%\u003c\/strong\u003e of the company’s total revenue, which amounted to \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eDistributors and Wholesalers\u003c\/h3\u003e\n\u003cp\u003eThe company utilizes a network of distributors and wholesalers to expand its market reach. As of 2023, Jiangxi Fushine collaborates with over \u003cstrong\u003e200 distributors\u003c\/strong\u003e, covering both urban and rural areas. This channel accounted for approximately \u003cstrong\u003e30%\u003c\/strong\u003e of the total sales, translating to roughly \u003cstrong\u003e¥720 million\u003c\/strong\u003e in revenue. The company has agreements with major wholesaling firms, such as China National Pharmaceutical Group, further enhancing its distribution capabilities.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\u003cp\u003eThe rise of e-commerce has prompted Jiangxi Fushine to strengthen its online presence. In 2023, online sales via platforms like Alibaba and JD.com represented about \u003cstrong\u003e20%\u003c\/strong\u003e of the total revenue, equating to around \u003cstrong\u003e¥480 million\u003c\/strong\u003e. The company’s online strategy includes engaging with various health forums and social media channels to increase visibility and customer interaction. In the first half of 2023 alone, there was a \u003cstrong\u003e25%\u003c\/strong\u003e increase in online sales compared to the previous year.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eChannel\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n    \u003cth\u003eRevenue (¥)\u003c\/th\u003e\n    \u003cth\u003eNumber of Partners\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e700\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDistributors and Wholesalers\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥720 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e200\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOnline Platforms\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥480 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eN\/A\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eJiangxi Fushine Pharmaceutical Co., Ltd. operates within a diverse range of customer segments that are critical to its business strategy. Each segment reflects specific needs and behaviors tailored to pharmaceutical products and services.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eThis segment represents a significant portion of Jiangxi Fushine's customer base. The company supplies a variety of pharmaceuticals, including antibiotics, pain relievers, and specialized medications. In 2022, hospitals and clinics accounted for approximately \u003cstrong\u003e45%\u003c\/strong\u003e of the company's total revenue, indicating a strong demand for its products within healthcare systems. The global hospital segment is projected to grow at a CAGR of \u003cstrong\u003e7.5%\u003c\/strong\u003e from 2023 to 2030, further supporting Fushine's sales potential in this area.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\u003cp\u003eRetail pharmacies are another vital segment for Jiangxi Fushine, contributing around \u003cstrong\u003e30%\u003c\/strong\u003e of the total revenue. The partnership with over \u003cstrong\u003e1,500\u003c\/strong\u003e retail pharmacies across China allows the company to reach a broad consumer base. The retail pharmacy market is expected to reach \u003cstrong\u003eUSD 1.1 trillion\u003c\/strong\u003e by 2025, growing at a CAGR of \u003cstrong\u003e3.8%\u003c\/strong\u003e from 2020. This growth projection indicates increasing opportunities for Fushine's product distribution.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eResearch institutions form a specialized customer segment for Jiangxi Fushine, focusing on advanced pharmaceutical research and development. This segment accounts for about \u003cstrong\u003e15%\u003c\/strong\u003e of total sales. Fushine collaborates with over \u003cstrong\u003e100\u003c\/strong\u003e research institutions, contributing to the development of innovative drugs. Investment in pharmaceutical R\u0026amp;D in China is expected to exceed \u003cstrong\u003eUSD 60 billion\u003c\/strong\u003e by 2025, providing significant growth opportunities for partnerships and product development in this sector.\u003c\/p\u003e\n\n\u003ch3\u003eExport Markets\u003c\/h3\u003e\n\u003cp\u003eExport markets are an emerging segment for Jiangxi Fushine, currently contributing around \u003cstrong\u003e10%\u003c\/strong\u003e of overall revenue. Fushine has expanded its operations to more than \u003cstrong\u003e30\u003c\/strong\u003e countries, including markets in Southeast Asia, Europe, and North America. The global pharmaceutical export market is projected to reach \u003cstrong\u003eUSD 1.42 trillion\u003c\/strong\u003e by 2025, growing at a CAGR of \u003cstrong\u003e6.5%\u003c\/strong\u003e. This segment has room for expansion as Fushine seeks to increase its international footprint.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eRevenue Share (%)\u003c\/th\u003e\n        \u003cth\u003eKey Data Points\u003c\/th\u003e\n        \u003cth\u003eGrowth Projections\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eRevenue: Significant contributors of antibiotics and specialized medications\u003c\/td\u003e\n        \u003ctd\u003eExpected CAGR: \u003cstrong\u003e7.5%\u003c\/strong\u003e (2023-2030)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003ePartnerships with over \u003cstrong\u003e1,500\u003c\/strong\u003e pharmacies\u003c\/td\u003e\n        \u003ctd\u003eMarket value: \u003cstrong\u003eUSD 1.1 trillion\u003c\/strong\u003e by 2025 (CAGR: \u003cstrong\u003e3.8%\u003c\/strong\u003e)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eCollaboration with over \u003cstrong\u003e100\u003c\/strong\u003e institutions\u003c\/td\u003e\n        \u003ctd\u003eInvestment in R\u0026amp;D: Exceeding \u003cstrong\u003eUSD 60 billion\u003c\/strong\u003e by 2025\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eExport Markets\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eExpansion to over \u003cstrong\u003e30\u003c\/strong\u003e countries\u003c\/td\u003e\n        \u003ctd\u003eGlobal market value: \u003cstrong\u003eUSD 1.42 trillion\u003c\/strong\u003e by 2025 (CAGR: \u003cstrong\u003e6.5%\u003c\/strong\u003e)\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eManufacturing expenses\u003c\/h3\u003e\n\u003cp\u003eFor Jiangxi Fushine Pharmaceutical Co., Ltd., manufacturing expenses constitute a significant portion of their overall cost structure. As of the latest financial reports, these expenses accounted for approximately \u003cstrong\u003e58%\u003c\/strong\u003e of total operational costs. In 2022, the company reported manufacturing costs of around \u003cstrong\u003eRMB 235 million\u003c\/strong\u003e, reflecting investments in advanced pharmaceutical production technologies and compliance with stringent quality control standards.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and development costs\u003c\/h3\u003e\n\u003cp\u003eInvestment in research and development (R\u0026amp;D) is crucial for Jiangxi Fushine to innovate and maintain its competitive edge. For the year 2022, R\u0026amp;D expenditures were estimated at \u003cstrong\u003eRMB 45 million\u003c\/strong\u003e, which represents about \u003cstrong\u003e10%\u003c\/strong\u003e of the total operational budget. This allocation supports the development of new drug formulations and enhancements of existing products.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution and logistics\u003c\/h3\u003e\n\u003cp\u003eDistribution and logistics costs have seen an uptick due to the expansion of Fushine's market reach. In 2022, these costs amounted to approximately \u003cstrong\u003eRMB 30 million\u003c\/strong\u003e, accounting for \u003cstrong\u003e7%\u003c\/strong\u003e of total expenses. The company has been optimizing its supply chain to reduce lead times and improve the efficiency of its distribution network.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and sales\u003c\/h3\u003e\n\u003cp\u003eJiangxi Fushine's marketing and sales expenses are pivotal to driving revenue growth. The company invested about \u003cstrong\u003eRMB 50 million\u003c\/strong\u003e in marketing efforts in 2022, which is around \u003cstrong\u003e12%\u003c\/strong\u003e of its total cost structure. This investment includes promotional activities, partnerships with healthcare providers, and branding initiatives to enhance market penetration.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Component\u003c\/th\u003e\n        \u003cth\u003e2022 Amount (RMB Million)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Costs\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Expenses\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e235\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e58%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch and Development\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e45\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution and Logistics\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e30\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e7%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Sales\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eTotal Costs\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e410\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJiangxi Fushine Pharmaceutical Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eJiangxi Fushine Pharmaceutical Co., Ltd. generates a significant portion of its revenue through direct product sales. In the fiscal year 2022, the company reported total product sales of approximately \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e, reflecting a year-on-year growth of \u003cstrong\u003e15%\u003c\/strong\u003e compared to 2021. The company's product lineup includes various pharmaceutical preparations, with a focus on traditional Chinese medicine and modern pharmaceuticals.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\u003cp\u003eThe company engages in licensing agreements, allowing it to earn revenue through collaborations with other pharmaceutical companies. In 2022, Jiangxi Fushine secured licensing revenue of around \u003cstrong\u003e¥300 million\u003c\/strong\u003e, which accounted for approximately \u003cstrong\u003e25%\u003c\/strong\u003e of its total revenue. These agreements help expand the company’s reach in international markets, capitalizing on its proprietary technologies and formulations.\u003c\/p\u003e\n\n\u003ch3\u003eExport Revenue\u003c\/h3\u003e\n\u003cp\u003eExport revenue serves as an essential revenue stream for Jiangxi Fushine Pharmaceutical. In 2022, the company's export revenue reached \u003cstrong\u003e¥500 million\u003c\/strong\u003e, representing a \u003cstrong\u003e20%\u003c\/strong\u003e increase from the previous year. The primary markets for exports include regions such as Southeast Asia and Europe, where the demand for traditional medicine continues to rise.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (¥)\u003c\/th\u003e\n        \u003cth\u003eYear-on-Year Growth (%)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduct Sales\u003c\/td\u003e\n        \u003ctd\u003e1,200,000,000\u003c\/td\u003e\n        \u003ctd\u003e15\u003c\/td\u003e\n        \u003ctd\u003e55\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Agreements\u003c\/td\u003e\n        \u003ctd\u003e300,000,000\u003c\/td\u003e\n        \u003ctd\u003e10\u003c\/td\u003e\n        \u003ctd\u003e25\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eExport Revenue\u003c\/td\u003e\n        \u003ctd\u003e500,000,000\u003c\/td\u003e\n        \u003ctd\u003e20\u003c\/td\u003e\n        \u003ctd\u003e20\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45679907963029,"sku":"300497sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/300497sz-business-model-canvas.png?v=1739126064","url":"https:\/\/dcf-analysis.com\/products\/300497sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}